Jae-hoon Song
MD, PhD
Medicine
Infectious Disease, Internal Medicine
Gangnam-gu, South Korea
Founder, Chairman, Chief Executive Officer, Dean
Dr. Jae-Hoon Song is an infectious disease physician/researcher and an entrepreneur based in Korea. He graduated from Seoul National University College of Medicine and trained at Seoul National University Hospital for an internship and residency in internal medicine. After military duty, he started his career as an infectious disease physician at Asan Medical Center, Seoul, Korea. He trained for a clinical fellowship at Mayo Clinic, Rochester, MN, USA. From 1995 to 2017, he worked at Samsung Medical Center in Seoul, Korea. During this period, he also served as President & CEO of the hospital and Dean of the School of Medicine at Sungkyunkwan University, Korea. He worked at CHA Bio Group as Chairman & CEO from 2018 to 2019, which is an international conglomerate of biotech and healthcare companies and hospitals in six countries.
Dr. Song founded Mint Venture Partners in 2020, a global venture platform for startups in the biotech and healthcare space. Mint Venture Partners has major programs for startup creation & technology incubation, startup investment, and startup growth acceleration globally. As an infectious disease physician/researcher, he initiated and founded the Asian Network for Surveillance of Resistant Pathogens (ANSORP) in 1996, which is an international research group for surveillance of antimicrobial resistance (AMR) in Asia. ANSORP has been carrying out many pivotal surveillance projects of AMR for almost 3 decades. As of 2023, a total of 126 hospitals in 14 Asian countries joined ANSORP programs for international collaboration to control and prevent AMR and infectious disease threats in the region.
Based on ANSORP activities, Dr. Song founded the Asia Pacific Foundation for Infectious Diseases (APFID) in 1999 to support and bolster international activities for the control and prevention of AMR and infectious diseases and also started to organize the International Symposium on Antimicrobial Agents and Resistance (ISAAR) in 1997, which becomes the most representative international meeting for this topic in the region. He has also served on a special committee by WHO (STAG-AMR) for preparing the “Global Strategy to combat antimicrobial resistance”. He has over 300 peer-reviewed publications.